IART Integra Lifesciences Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IART

Price (delayed)

$54.03

Market cap

$4.41B

P/E Ratio

24.78

Dividend/share

N/A

EPS

$2.18

Enterprise value

$5.57B

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra ...

Highlights
The stock's price to earnings (P/E) is 54% less than its 5-year quarterly average of 54.3 and 9% less than its last 4 quarters average of 27.1
IART's EPS is up by 9% year-on-year and by 5% since the previous quarter
IART's quick ratio is down by 10% from the previous quarter but it is up by 2.3% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.integralife.com
Peers: SYK TFX XRAY CNMD

Key stats

What are the main financial stats of IART
Market
Shares outstanding
81.64M
Market cap
$4.41B
Enterprise value
$5.57B
Valuations
Price to earnings (P/E)
24.78
Price to book (P/B)
2.5
Price to sales (P/S)
2.88
EV/EBIT
21.14
EV/EBITDA
14.48
EV/Sales
3.58
Earnings
Revenue
$1.56B
EBIT
$263.49M
EBITDA
$384.6M
Free cash flow
$233.27M
Per share
EPS
$2.18
Free cash flow per share
$2.81
Book value per share
$21.6
Revenue per share
$18.77
TBVPS
$20.78
Balance sheet
Total assets
$3.89B
Total liabilities
$2.09B
Debt
$1.62B
Equity
$1.8B
Working capital
$840.59M
Liquidity
Debt to equity
0.9
Current ratio
3.62
Quick ratio
2.24
Net debt/EBITDA
3.01
Margins
EBITDA margin
24.7%
Gross margin
62.3%
Net margin
11.6%
Operating margin
15.3%
Efficiency
Return on assets
4.8%
Return on equity
10.6%
Return on invested capital
10.2%
Return on capital employed
7.4%
Return on sales
16.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
1.1%
1 week
2.7%
1 month
-6.1%
1 year
-15.61%
YTD
-3.64%
QTD
-3.64%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.56B
Gross profit
$970.31M
Operating income
$238.92M
Net income
$180.55M
Gross margin
62.3%
Net margin
11.6%
The operating income has grown by 21% year-on-year and by 4.2% since the previous quarter
IART's operating margin is up by 20% year-on-year and by 4.1% since the previous quarter
Integra Lifesciences Holdings's net income has increased by 7% YoY and by 4.4% from the previous quarter
The net margin is up by 5% year-on-year and by 4.5% since the previous quarter

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
P/E
24.78
P/B
2.5
P/S
2.88
EV/EBIT
21.14
EV/EBITDA
14.48
EV/Sales
3.58
The stock's price to earnings (P/E) is 54% less than its 5-year quarterly average of 54.3 and 9% less than its last 4 quarters average of 27.1
IART's EPS is up by 9% year-on-year and by 5% since the previous quarter
The P/B is 24% lower than the 5-year quarterly average of 3.3 and 7% lower than the last 4 quarters average of 2.7
The equity has increased by 7% year-on-year and by 4.6% since the previous quarter
The price to sales (P/S) is 13% less than the 5-year quarterly average of 3.3

Efficiency

How efficient is Integra Lifesciences Holdings business performance
IART's ROA is up by 7% YoY and by 4.3% QoQ
IART's return on sales is up by 6% since the previous quarter
IART's return on invested capital is down by 6% year-on-year but it is up by 4.1% since the previous quarter

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 87% higher than its total liabilities
IART's quick ratio is down by 10% from the previous quarter but it is up by 2.3% YoY
The current ratio has declined by 8% since the previous quarter but it has grown by 7% year-on-year
The debt is 10% smaller than the equity
Integra Lifesciences Holdings's debt to equity has decreased by 9% QoQ and by 8% YoY
The equity has increased by 7% year-on-year and by 4.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.